Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis

The two already well-known substances of the Cyclosporine (C) and FK506 (tacrolimus) (F)-series serve as building blocks. They are connected via a so called linker -- here shown as a chain. Credit: DZNE / C. Schwickart

A new substance class for the treatment of multiple sclerosis and other neurodegenerative diseases now promises increased efficacy paired with fewer side effects.

To achieve this, a team of scientists under the leadership of Prof. Gunter Fischer ( Research Unit for Enzymology of Protein Folding, Halle/Saale, Germany) and Dr. Frank Striggow (German Center for (DZNE)) have combined two already approved pharmaceutical substances with each other using a chemical linker structure. The objectives of this combination are to ensure maximum brain cell protection on the one hand and the suppression of unwanted side effects on the other. The new class of substances has now been registered with the as the DZNE's first patent in the form of a joint with the Max Planck Research Unit. "The patent approval process can take several years. During this phase we are planning to conclude the pre-clinical development. It is our aim to start with clinical research and development at the earliest possible time. Overall, we have identified substantial therapeutic potential as far as chronic and age-related neurodegenerative diseases are concerned," comments Dr. Frank Striggow.

Multiple sclerosis is an inflammatory disease that affects the . It destroys the insulation of the nerve cell signaling system, the of the neural axons. The consequence of this process is the malfunction of signaling and finally cell death resulting in permanent neurological problems. The cause of multiple sclerosis is that the body itself attacks the cellular components of the myelin sheaths, the oligodendrocytes. Hence, the team of scientists under the direction of Prof. Gunter Fischer and Dr. Frank Striggow embarked on a search for intervention options that could protect from these attacks. The goal was not only to prevent the damage and loss of brain cells, but also to develop a medication that has a positive impact on cell regeneration.

The used components of the Cyclosporine and FK506 (tacrolimus)-series have been utilized in a chemically slightly altered form as immunosuppressant medications for a long time. Both suppress the cellular immune defenses. This effect is necessary in conjunction with organ transplants, but otherwise problematic for the organism. The specific combination of the two substances amplifies the protective effect on the thanks to different but synergistic efficacy mechanisms. The impact on the immune defense is reduced at the same time, which results in fewer side effects. Both of these achievements were corroborated by experiments. An application for a patent protecting this new class of active ingredients has now been filed. Ascenion GmbH and Max Planck Innovation both attend the project as utilization partners of the DZNE and of the Max Planck Society.

add to favorites email to friend print save as pdf

Related Stories

Multiple sclerosis: Damaged myelin not the trigger

Feb 27, 2012

Damaged myelin in the brain and spinal cord does not cause the autoimmune disease multiple sclerosis (MS), neuroimmunologists from the University of Zurich have now demonstrated in collaboration with researchers from Berlin, ...

Researchers decode a puzzling movement disorder

Nov 25, 2011

Neurodegenerative diseases represent one of the greatest challenges of our aging society. However, investigation into these diseases is made particularly difficult due to the limited availability of human brain tissue. Scientists ...

Recommended for you

Added benefit of vedolizumab is not proven

1 hour ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments